Warning lights
Signals from the annual accounts, the CBE and the Official Gazette, each with its threshold and source. No score, no verdict.
-
Negative equity NBB
More debt than assets in 2 of the last 4 fiscal years.
Financials
Financial year 2025
ImmuneWatch from Antwerpen, company number BE0774472942, closed financial year 2025 with a result of € 8,523 after tax. For that financial year ImmuneWatch recorded a gross margin of € 272,476 and equity of € -30,203. Compared with financial year 2024, the result moved from € -80,581 to € 8,523. Profitable, and profit is growing. More debts than assets. High debts against a small own buffer. The most recent annual accounts were filed with the National Bank of Belgium on July 20, 2026.
€ -30,203
▲ € 8,523 vs 2024
Assets minus debts, by the books. What is left if everything were sold and paid today.
€ 8,523
▲ still € 80,581 loss in 2024
Profit after tax over the fiscal year.
€ 59,129
▼ 73% vs 2024
Cash and bank balances on the last day of the fiscal year.
Stays in the company
No dividend for 2025. Retained profit grew to € -261,782.
People and assets in 2025
€ 56,281
▲ 11% vs 2024
Payroll staff only. What the director pays themselves is already netted into the gross margin and is not shown separately in the accounts.
€ 1,464
▼ 38% vs 2024
Book value of vehicles, furniture and equipment.
Debts at end 2025
€ 15,000
Loans from banks and other lenders, long and short.
€ 38,105
▲ 5% vs 2024
Supplier invoices still open on the last day of the fiscal year.
€ 7,825
▲ 10% vs 2024
Wages, holiday pay and social contributions still to pay. No outstanding taxes.
Want to see how much further we take a dossier in the Pro version? Open the free De Lijn example and give feedback →
| 2022 | 2023 | 2024 | 2025 | Change 2024 → 2025 | |
|---|---|---|---|---|---|
| Gross margin | € -100,841 | € 288,934 | € 109,909 | € 272,476 | ▲ 148% |
| Profit after taxes | € -121,777 | € -67,947 | € -80,581 | € 8,523 | ▲ € 89,104 |
| Equity | € 109,802 | € 41,855 | € -38,726 | € -30,203 | ▲ € 8,523 |
| Total debts | € 86,104 | € 352,837 | € 338,526 | € 203,943 | ▼ 40% |
| Cash | € 176,299 | € 321,393 | € 222,439 | € 59,129 | ▼ 73% |
| Retained profit | € -121,777 | € -189,724 | € -270,305 | € -261,782 | ▲ € 8,523 |
| Bank debt | € 15,000 | € 15,000 | € 15,000 | € 15,000 | |
| Balance sheet total | € 195,906 | € 394,691 | € 299,800 | € 173,740 | ▼ 42% |
Key figures of ImmuneWatch, fiscal years 2022 to 2025, from the annual accounts filed with the National Bank of Belgium.Next annual account (fiscal year 2026) expected before 31 July 2027.
What happened to ImmuneWatch?
What happened at ImmuneWatch in recent years, according to the Belgian Official Gazette, the CBE and the National Bank:
- New annual accounts for financial year 2025: profit of € 8,523. Source: NBB ↗
- Cawu BV became a director. NBB
- New establishment in Antwerpen. KBO
- Start of the company according to the CBE. KBO
- Kris Laukens became a director. NBB
- Pieter Meysman became a director. NBB
- Tom Bosschaerts became a director. NBB
- Benson Ogunjimi became a director. NBB
In short
From € 121,777 loss in 2022 to € 8,523 profit in 2025.
Best year ever: 2025, with € 8,523 profit.
A new publication or filing at ImmuneWatch? We notify you, reason included.
Follow ImmuneWatchDatabakkes Pro
Know what changes at your customers, suppliers and competitors. Without reading an annual account.
- Follow them in one folder Every company in your folder gets this full dossier: household book, all fiscal years, benchmark against companies of the same size.
- We alert you, with the reason New annual account, Official Gazette publication or status change: you get what changed and where it says so.
- In bulk too, and in ChatGPT and Claude Upload your customer list and get the warning signs back per company. Or ask in your own AI assistant, with this register as the source.
Databakkes Pro is being built. Sign up now and you are first in line for an invitation, with a month to try without a credit card.
De Lijn 8 June 2026 New annual account 2025
filed on 8 June 2026
What was left
€ 20 k ▼ 91%
Money in the bank
€ 178 k ▼ 98%
Open the dossier →
NMBS 8 June 2026 New annual account 2025 What was left ▼ 80%
bpost 18 May 2026 New annual account 2025 What was left from loss to profit
Management
Behind ImmuneWatch are Kris Laukens, Pieter Meysman, Tom Bosschaerts, Cawu BV and Benson Ogunjimi. Tom Bosschaerts is also behind BOLANTO.
Establishments
Establishment units
Physical locations of this company
Lange Gasthuisstraat 29-31
2000 Antwerpen
Who else lives here?
A building full of entrepreneurs or one very busy letterbox? Another 7 companies are registered at this address.
All companies at this address →DATYLON
€ -7,599 gross margin · 2025
DE SERRE
€ 12,504 gross margin · 2025
DATYLON TECHNOLOGIES
€ -15,452 gross margin · 2025
HELPPER
€ 2.6 million gross margin · 2025
Salvus Health
€ 153,569 gross margin · 2025
+2 more
What is an establishment unit? An establishment unit is a geographically identifiable place where activities of the enterprise are carried out.
Details
- Company number
- 0774.472.942
- VAT number
- BE 0774.472.942
- Registered office
- Lange Gasthuisstraat 29-31, 2000 Antwerpen
- Names & denominations
- ImmuneWatch
- Enterprise type
- Rechtspersoon
- Legal form
- Private limited company
- Legal situation
- Normale toestand
- Start date
- 23 September 2021
- Peppol
- Active · Active since 2 May 2025
- Activities · NACE
Speur- en ontwikkelingswerk op biotechnologisch gebied